Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is no way it trades flat with this much volume. Retail orders are being "parked" in the darkpool. That is the only way to pin the price like this.
Great way to start the year! I finally have lots in the Green.
Didn’t know he has such a big stake in this stock. From now on, I’ll listen to his advice??
Again, then WHY are you still here? (Not expecting an answer).
Benny / Z I only owned 300 or so shares . Last sale was as follows
payors usually want patient to fail on Benlysta
I sold on the last buyout rumor months ago
You just figured that out now? He takes his cue from what he sees in his partner’s practice.
You just figured that out now? He takes his cue from what he sees in his partner’s practice.
If you "sold on the last buyout rumor months ago" then why are you still here? I think you are lying.
Take the $ and run
Lupkynis may be the best for severe LN but payors usually want patient to fail on Benlysta ( which is cheaper ) first .
Altho approved in the EU , doubt any country will provide reimbursement.
May be wrong but I sold on the last buyout rumor months ago and don’t intend to buy back now
Good luck
Kiwi
No bump in the road ahead. How can you go wrong with best LN medicine for an unmet medical need? Haven’t heard from the ex CEO who claimed to be better than PG.
this decision comes down in 6 months instead of a year, now we have full year for offers, wonder if Otsuka will make a bid soon.
As expected, the suit settled. Let the buyout rumors commence
huge volume, nice way to start the year!
hope it caught some naked shorts! about time
Looks like the suit finally settled: https://ir.auriniapharma.com/press-releases/detail/272
that should read 3 trillion not 3 billion
For Canadians. US taxpayers can sell through tomorrow and claim the loss on the 2022 taxes.
At least the tax loss selling is over..
I think it gets resolved by the summer as I recall
Happy New Year, everyone. 2023 will be an improvement. It has to be. I have had one lingering thought (just one...ha) all year long: This potential patent issue would have been well known by Master Glickman "way back when". I can't help but believe he would have dealt with it at the time had there been anything to it. So....I remain in the camp that this thing is, hopefully, "much ado about nothing". That doesn't mean Aurinia wouldn't compromise just to save litigation fees. Companies do that all the time. Do we have any tentative dates when this thing will be decided?
Those of us still here remain hopeful that after the lawsuit settles the company will be sold. I'd guess a settlement will bring us back to 10 and a buyout at 15-20. Far less than we were expecting but a lot more than it is now. For now it's dead money but so are most other small bios now.
$3,000,000,000 wiped off market cap in a little over a year. How do you address that in 2023 AGM, maybe postpone to 2024 lol.
This is AMRN 2.0
RMB Feedback from my wife's Nephrology dept . Lupkynis appears the best for severe LN, however Benlysta is cheaper and insurers want patient to fail on Benlysta first... before covering for Lupkynis .
So Co is burning thru cash on hand as it try's to overcome payor resistance .
OT ..spec biotech 4 U ...SLNO . If interested post to me on that board and I'll fill U in
Good luck
Kiwi
Not much to argue with in your post
first of all I would have presented to the shareholder a buyout if there was one presented, or if it was in the price range above the then trading price of 34.00 I would have taken the buyout. It was obvious up to that point peter and his staff neither had the experience to go this alone.
If there was no buyout First of all I would not have taken a pay increase and if the market said the drug was too expensive, Selling at a smaller profit and reaching a greater number of patients would be the first priority.
Second I would have looked at all the dead weight and over paid management/employees and cut staff because obviously those there were/and those there now are not performing up to the needs of the company.
you can scoff at me all you want, I am not happy about being correct about peters ability to run this company. He once stated shareholder value and getting the drug to as many as needed it as possible. so far he has done neither.
The share price never should have fallen below the price it was after FDA approval, that is all on management.
you can continue to stand up for perter all you want and that just makes him pleased ap punch, fact to date show that peter only cares about peter and his over paid salary proves.
He cannot even get the sales high enough for the company to pay it's own way and when the slush fund runs out so does all of our value.
We would be lucky to get a 10-15 dollar buyout offer right now, and if we could get that high I would run and never look back.
I am sure you of all shareholders is just tickled to be down 30.00 a share.
And each side can “find” their experts to espouse their line. Up to each side to impeach the other.
Actually it leaves more questions than answers. Need two opinions: scientist to say how similar or dissimilar it is and patent attorney opinion on how similarities infringe on AUPH patent. Both of which I'm sure AUPH had done or they would not have filed suit.
AUPH Patent 2008
https://patents.google.com/patent/US20090092665A1/en
Sun Pharma Patent 2017
https://patents.google.com/patent/US10918694B2/en
Thanks for the great DD Cosa
Had some time to look into Dry Eye. Its very twisted. Suns patent looks more detailed as Auven went through phases of testing before selling to Sun. AUPH started there phases after.
(2014) AUPH has a dry eye patent from purchasing Lux Bioscience
https://patents.google.com/patent/US20090092665A1/en
(2009)Ashim Mitra worked with Lux Bioscience
LX214, developed in cooperation with Ashim Mitra, Ph.D., University of Missouri Curator’s Professor of Pharmacy and Director of Translational Research at UMKC School of Medicine School of Pharmacy, University of Missouri-Kansas City, is a proprietary formulation of Lux Biosciences’ next generation calcineurin inhibitor, voclosporin
https://www.ophthalmologyweb.com/1315-News/32734-Lux-Biosciences-Reports-Phase-1-Safety-Results-And-Open-Label-Efficacy-Results-For-LX214-A-Potential-Best-In-Class-Treatment-For-Dry-Eye/
(2014)Looks like Ashim shared the data with Auven Therapeutics which conducted their own phases
https://www.fiercebiotech.com/biotech/auven-therapeutics-announces-positive-results-from-pivotal-clinical-trial-of-seciera-otx
(2016)This is how Sun got the formula for Cequa
Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma.
https://www.globenewswire.com/news-release/2016/10/26/883163/0/en/Auven-Therapeutics-Announces-Sale-of-Ocular-Technologies-to-Sun-Pharma.html
(2017) Sun files patent.
https://patents.google.com/patent/US10918694B2/en
Then another lawsuit from University and Undergrad student at the time. This was settled.
A Missouri graduate who said his professor (Ashim Mitra) stole his invention for a drug delivery system will share in its profits under a settlement that also gives the University of Missouri System a cut of the revenue
https://www.seattletimes.com/business/missouri-graduate-to-share-in-invention-profits-under-deal/
Another fresh 52 week low. But a reversal now so hopefully we start the climb back up.
Every morning big candle wick down. I know you guys notice it too. Then they cover and it doesn't need to be reported. Even with it's headwinds this should not be trading at $4.
Yep, the EU slamming the door on much cheaper drugs so in a way not surprising.
Ouch! Not expected.. Cost of drug..
In their draft guidance, NICE not recommending V. Not a final decision but hopefully a bargaining ploy, but easy to understand the sagging stock price in light of this.
https://www.nice.org.uk/guidance/GID-TA10878/documents/129
Question Zzatt. How many scientists do they have. Would it be prudent for management to just hire more and more scientists, since all that matters in biotech is scientists.
I wish you were a bit more specific in how management should improve.
I'm sure they would be very happy to get some solid, expert advice, after all,
they all hold lots of stock in Aurinia. Probably more than you.
How would you have done differently it if you were the CEO?
our only hurdle to success is management.!
like I said bill is just here for the cash cow until money runs out. then he just runs.
Insanity! Market cap just 284m over cash
RMB. re your view of a buyout for " something between 12 and 18 bucks a share."
Doubt it
AUPH only added 80 patients on Lupkynis from June thru Sept Qt 2022 ....and only 50% remain on the drug after 1 yr ....latest earning report .
Lupkynis is an expensive drug and IMHO mostly prescribed for severe LN.
Lup faces significant payer ( insurer ) resistance who often require the patient to fail Benlysta first .
Co still has a lot of cash ..$376 m in latest qt ....but IMHO unlikely to find favorable reimbursement easily in the EU or UK .
Doubt any BP is interested .
Good luck
Kiwi
Well, at this price not much more downside left right? With the exposed fiasco last year (premature press release claiming a sale of the company that got someone fired) it is fairly clear that management knows they need to sell the company, so hopefully their poor performance GIA drives that point home more forcefully and a deal materializes -- not at the wild valuations mentioned here last year but something between 12 and 18 bucks a share.
If that’s your rationale, May I ask why you’re still invested in it?
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |